Showing 5531-5540 of 8888 results for "".
- Estée Lauder Companies Anti-Aging Research On Skin Demonstrates Efficacy of Actives and Novel Technologies in Skin Researchhttps://practicaldermatology.com/news/este-lauder-companies-anti-aging-research-on-skin-demonstrates-efficacy-of-actives-and-novel-technologies-in-skin-research/2457874/The Estée Lauder Companies Research & Development (R&D) presented research focused on new findings in anti-aging skin research at the 2018 American Academy of Dermatology Annual Meeting in San Diego. The following reserach was presented at poster presentations at the AAD me
- Merkel Cell Carcinoma Is On The Risehttps://practicaldermatology.com/news/merkel-cell-carcinoma-is-on-the-rise/2457879/Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meetin
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell
- Aqua Pharmaceuticals Supports Camp Discoveryhttps://practicaldermatology.com/news/aqua-pharmaceuticals-supports-camp-discovery/2457884/Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- BTL Aesthetics Unveils Body by BTL Campaignhttps://practicaldermatology.com/news/btl-aesthetics-unveils-body-by-btl-campaign/2457890/BTL Aesthetics is celebrating the brand's innovation with a first-of-its-kind campaign for the professional aesthetics industry emphasizing full body results. The Body by BTL campaign showcases the brand's breadth of treatment solu
- Denova Research and Illinois Dermatology Institute Partner for Clinical Researchhttps://practicaldermatology.com/news/denova-research-and-illinois-dermatology-institute-partner-for-clinical-research/2457894/DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Research has over 10 years’ experience, 110 publications and 76 clinical trials; many of whi
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- Bonti Takes Aim at Scar Reduction with Shine Clinical Programhttps://practicaldermatology.com/news/bonti-takes-aim-at-scar-reduction-with-shine-clinical-program/2457897/Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized